ArticleJournal of functional biomaterials2026
Injectable Hydroxyapatite and Tetracalcium Phosphate Granules Combined with Autologous Bone Marrow Concentrate: Toward Shape-Adaptive, Single-Step Bone Regeneration.
Article in Journal of functional biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundInjectable bone graft substitutes offer a practical alternative to preformed ceramic scaffolds by adapting to irregular bone defects while preserving osteoconductive properties. This study investigated the in vivo performance of hydroxyapatite/tetracalcium phosphate (HA/TTCP) granules, uncoated or alginate-coated, with or without autologous ovine bone marrow concentrate (oBMC), in a standardized sheep bone defect model.
methodsoBMC was characterized for cellular composition, viability, and recovery. Implanted HA/TTCP formulations were evaluated after 6 and 12 weeks by micro-computed tomography and histomorphometry.
resultsUncoated HA/TTCP granules promoted bone formation, integrating with host bone. Alginate coating improved injectability and handling but influenced granule organization and degradation. Uncoated HA/TTCP + oBMC showed a more favorable response than the coated formulation, with higher bone-to-implant contact (
conclusionsInjectable HA/TTCP granules + oBMC represent a promising single-step strategy for irregular bone defects, although further coating optimization is needed to preserve biological performance while maximizing handling advantages.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.